On 29 May 2015, FIT Biotech Oy (‘FIT Biotech’ or the ‘Company’) announced a share offering (the ‘Offering’) in which the Company offered a maximum of 5,418,578 new K shares in the Company (the ‘Offer Shares’) for subscription. The Offering was comprised of (i) an institutional offering, where Offer Shares were offered to institutional investors in Finland and internationally in certain jurisdictions subject to the fulfilment of requirements based on local laws; (ii) a public offering, where Offer Shares were offered to the public in Finland; and (iii) a conversion offering, where Offer Shares were offered to the holders of the Company’s convertible capital loans and subordinated loans and to one loan holder. At the same time, the Company announced that it would apply for the admission to trading of the K shares on the multilateral First North Finland market maintained by NASDAQ OMX Helsinki Ltd (the ‘Helsinki Stock Exchange’).
